Puma Biotechnology (PBYI) Announces Late-Breaking Oral Presentation On Neratinib In NSCLC With HER2 Mutations At ESMO 2014
9/3/2014 8:58:09 AM
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced that data from a Phase II clinical trial of its investigational drug PB272 (neratinib) for the treatment of patients with non-small cell lung cancer (NSCLC) that has a HER2 mutation will be presented as a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) 2014 Congress, September 26-30, in Madrid, Spain. The presentation entitled “Neratinib with or without temsirolimus in patients with non-small cell lung cancer carrying HER2 somatic mutations: An international randomized Phase II study” will occur on September 29, 2014.
Hey, check out all the research scientist jobs. Post your resume today!
comments powered by